Angela Shen, MD, MBA, serves as Vice President of Strategic Innovation Leaders at Mass General Brigham (MGB) Innovation and Head of Regulatory at the MGB Gene and Cell Therapy Institute. Dr. Shen brings extensive expertise in translational medicine, clinical development, and regulatory affairs, driving the advancement of novel therapies. A seasoned biotech executive with over 20 years of industry experience, Dr. Shen has led the development of innovative therapies across all stages of drug development, including IND filings, first-in-human trials, registrational trials, and NDA/BLA filings. Before joining MGB, she served as Chief Medical Officer (CMO) for multiple successful venture-backed biotech startups. During her tenure at Novartis, Dr. Shen played a key role in the in-licensing of the University of Pennsylvania’s CAR-T technology and led the clinical team that designed and launched industry’s first multi-site registrational CAR-T trial, which led to the landmark FDA approval of Kymriah. Throughout her career, Dr. Shen has played a pivotal role in advancing the development of oncology and rare disease drugs across various companies.